$3.48 DeepSeek V4: 93.5% Coding Beats Claude Opus 7x Cheaper

DeepSeek V4 debuts at $3.48 per million output tokens, scoring 93.5% on LiveCodeBench and undercutting Claude Opus by 7x in coding benchmark cost.

DeepSeek V4 preview launched on April 24, 2026, with V4-Pro output priced at $3.48 per million tokens — roughly 7x cheaper than Claude Opus 4.6’s $25. The model posts 93.5% on LiveCodeBench and a Codeforces rating of 3,206, edging past both Claude and GPT-5.4 on coding while using just 10% of V3.2’s KV cache at 1M-token context. That same week, Tencent and Alibaba opened discussions to invest at a $20 billion-plus valuation, the first outside capital in DeepSeek’s history. Read more »

4-Month Triple to $30B ARR: Anthropic Revenue Tops OpenAI

Anthropic revenue hits $30B ARR after tripling in four months, surpassing OpenAI's $24B as over 1,000 enterprises pay $1M+ annually and eight of the Fortune 10 adopt Claude.

$30 billion. Four months ago, that number belonged to OpenAI alone. On April 7, 2026, Anthropic revenue on an annualized run-rate basis (ARR, a standard SaaS gauge that multiplies monthly revenue by twelve) crossed $30B — and the company became the first AI startup to pass the chief rival that dominated the sector for three straight years. Read more »

Novo Nordisk × OpenAI: AI Drug Discovery Arms Race Begins

Drug discovery competition intensifies as Novo Nordisk teams with OpenAI while Eli Lilly deploys a $3.75B AI war chest including a $2.75B Insilico Medicine deal.

Drug discovery just entered a new era. On April 14, 2026, Danish pharmaceutical giant Novo Nordisk — the maker of Ozempic and Wegovy — announced a sweeping partnership with OpenAI to embed artificial intelligence agents across its entire operational chain. From genomic data analysis to supply chain optimization, every stage of how a drug is found, made, and delivered is now on the table. Read more »